Sermorelin (GHRH 1-29) — 5mg

Sermorelin is a synthetic GHRH analog consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It is the shortest GHRH fragment that still possesses full biological activity. Each vial contains 5mg of lyophilized Sermorelin, ≥99% purity, HPLC tested with COA. Sermorelin stimulates the pituitary in a direct, physiological way to produce and release growth hormone via the same receptor and signaling mechanism as endogenous GHRH. Unlike exogenous GH (somatropin), Sermorelin preserves the negative feedback regulation of the hypothalamus-pituitary axis, preventing oversuppression. In clinical settings Sermorelin is prescribed for adult growth hormone deficiency as an alternative to synthetic GH. In research protocols subcutaneous doses of 200–500mcg per day are used, preferably before sleep. Half-life is approximately 10–20 minutes. Reconstitution with bacteriostatic water is required. For laboratory and research purposes only.

Post Cycle Therapy (PCT) is not required after Sermorelin use. It does not affect the hypothalamus-pituitary-gonadal axis.